Jeffrey Lawrence Schwartz - 24 May 2023 Form 4 Insider Report for SpringWorks Therapeutics, Inc. (SWTX)

Role: Director
Signature: /s/ Jeffrey Schwartz
Issuer symbol: SWTX
Transactions as of: 24 May 2023
Net transactions value: $0
Form type: 4
Filing time: 25 May 2023, 17:04:48 UTC
Previous filing: 05 May 2023
Next filing: 28 May 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SWTX	Common Stock	Award	$0	+4,648	+78%	$0.000000	10,572	24 May 2023	Direct	F1
holding	SWTX	Common Stock						3,081,307	24 May 2023	See footnote	F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SWTX	Stock Option (Right to Buy)	Award	$0	+13,774		$0.000000	13,774	24 May 2023	Common Stock	13,774	$32.27	Direct	F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
F2	This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.
F3	The options shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
F4	Represents shares of common stock held directly by BC SW, LP. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of BC SW, LP. The Reporting Person is a Partner of BCLSI. As a result, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC SW, LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.